Furthermore, neither Zileuton nor Montelukast had an impact on cell growth of bone marrow-derived BCR-ABL-CD34+CD38- cells from CML patients in long-term culture-initiating cell and colony assays [75]. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.